These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 9914870)
1. Advances in the biology and treatment of multiple myeloma. Varterasian ML Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870 [TBL] [Abstract][Full Text] [Related]
2. Biologic and clinical advances in multiple myeloma. Varterasian ML Oncology (Williston Park); 1995 May; 9(5):417-24; discussion 429-30. PubMed ID: 7547203 [TBL] [Abstract][Full Text] [Related]
3. Advances in biology and therapy of multiple myeloma. Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785 [TBL] [Abstract][Full Text] [Related]
4. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712 [TBL] [Abstract][Full Text] [Related]
6. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Gieseler F; Nüssler V Leukemia; 1997 Dec; 11 Suppl 5():S1-4. PubMed ID: 9436930 [TBL] [Abstract][Full Text] [Related]
7. Molecular aspects of multiple myeloma. Kastrinakis NG; Gorgoulis VG; Foukas PG; Dimopoulos MA; Kittas C Ann Oncol; 2000 Oct; 11(10):1217-28. PubMed ID: 11106109 [TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231 [TBL] [Abstract][Full Text] [Related]
9. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718 [No Abstract] [Full Text] [Related]
10. Apoptotic signaling in multiple myeloma: therapeutic implications. Chauhan D; Hideshima T; Anderson KC Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804 [TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells in multiple myeloma. Gunes EG; Gunes M; Yu J; Janakiram M Trends Cancer; 2024 Aug; 10(8):733-748. PubMed ID: 38971642 [TBL] [Abstract][Full Text] [Related]
12. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Greipp PR; Lust JA Stem Cells; 1995 Aug; 13 Suppl 2():10-21. PubMed ID: 8520496 [TBL] [Abstract][Full Text] [Related]
13. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Gieseler F; Nüssler V Leukemia; 1998 Jul; 12(7):1009-12. PubMed ID: 9665183 [TBL] [Abstract][Full Text] [Related]
15. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307 [TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Nefedova Y; Landowski TH; Dalton WS Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386 [TBL] [Abstract][Full Text] [Related]
18. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864 [TBL] [Abstract][Full Text] [Related]